Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reached a new milestone in the field of total shoulder arthroplasty with the recent Food and Drug Administration (FDA) approval for its SidusStem-Free Shoulder system in the United States. Following this approval, the Sidus system will be available in the country from the first quarter of 2018.
This total shoulder arthroplasty solution claims to benefit patients with a good bone stock and also at the same time, complaining of either osteoarthritis, post-traumatic arthrosis, focal avascular necrosis of the humeral head or for those having undergone previous surgeries of the shoulder that do not compromise the fixation.
Per Zimmer Biomet, the system is designed to restore a patient's anatomy, preserve bone stock and offers improved pre to post-operative patient outcomes.
We are encouraged to note that the Sidus Stem-Free Shoulder system offers minimal bone resection in total shoulder arthroplasty. Zimmer Biomet claimed that this advanced approach will reduce pain and restore a range of motions.
The Sidus system was first introduced in Europe in 2012 and the company initiated a clinical study in the United States in 2015. Going by the strong clinical performance that the Sidus Stem-Free Shoulder system has demonstrated over time, Zimmer Biomet seems highly optimistic about showing the impression of customer adoption.
Per an article published in OrthoSpineNews, in 2016, the global shoulder arthroplasty market was valued at $1,090.0 million. By 2023, the same is expected to scale up to $1,866.3 million, registering a CAGR of 8.1% during the forecast period. This promising data indicates what a timely and strategic role the latest FDA approval is going to play in favor of Zimmer Biomet.
Solid Stock Performance
In the last 30 days, Zimmer Biomet has been trading above the broader industry. The company has gained 11% versus the broader industry’s 5.2% rise. Also, the company has outperformed the S&P 500’s 3.1% gain over the same time frame.
Zacks Rank & Key Picks
Zimmer Biomet carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are ABIOMED Inc. (NASDAQ:ABMD) , Tactile Systems Technology (NASDAQ:TCMD) and Intuitive Surgical Inc. (NASDAQ:ISRG) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
ABIOMED has a long-term expected earnings growth rate of 31.5%. The stock has rallied 72.8% in the last year.
Tactile Systems has a long-term expected growth rate of 20%. The stock has soared 81.5% in the last year.
Intuitive Surgical has a long-term expected growth rate of 9.2%. Over the last 6 months, the stock has rallied 20.1%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Tactile Systems Technology, Inc. (TCMD): Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report
Original post
Zacks Investment Research